Podcast Episodes
Back to Search
243: George Scangos' retirement, annual Covid vaccines, an Alzheimer's drug rejection
George Scangos, the CEO of Vir Biotechnology, joins us to discuss his retirement and offer some perspective and lessons from a remarkable, 40-year ca…
3 years, 9 months ago
242: How blockbusters get made, new vaccines for RSV, and mRNA's Q score
Journalist Nathan Vardi joins us to talk about his new book delving into the race to develop the lifesaving cancer drug now called Imbruvica, involvi…
3 years, 9 months ago
241: #JPM23 in review, the year ahead, & the merits of Miami
With the 2023 J.P. Morgan Healthcare Conference drawing to a close, we look back on the biggest news of the meeting, what it means for the year in bi…
3 years, 9 months ago
240: #JPM23, the future of Alzheimer's, & rising Covid variants
First, we delve into a sweeping congressional investigation into the FDA's approval of the last treatment for Alzheimer's disease and what it means f…
3 years, 9 months ago
239: 2022 in review, CEO indictments, & the year ahead
We look back on the biggest biotech stories of 2022 and how, despite some meaningful advances in Alzheimer's disease and gene therapy, the industry s…
3 years, 10 months ago
238: Leaky health data, ASH22, & what it takes to get booed by your peers
Katie Palmer, STAT's health tech correspondent, joins us to explain how the explosive popularity of telehealth is putting sensitive patient informati…
3 years, 10 months ago
237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing
STAT's Elaine Chen joins us to explain how the escalating demand for a potent diabetes drug is putting patients with obesity in a difficult situation…
3 years, 10 months ago
236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval
STAT Washington correspondent Rachel Cohrs joins us to explain how PhRMA, the all-powerful lobbying group, lost its edge in a fight over drug-pricing…
3 years, 11 months ago
235: LIVE from the STAT Summit
How do Alzheimer’s drugs even work? Can biotech people bake? And do we even like one another? Recorded live from the 2022 STAT Summit, we discuss the…
3 years, 11 months ago
234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy
STAT Washington correspondent Sarah Owermohle joins us to explain how this week's midterm elections will affect health and medicine, and what the pol…
3 years, 11 months ago